Author

K. King

Observed names: K King, KM King

Institutions: University of Alberta, Cross Cancer Institute

Observed institutions: Alberta Health Services, BC Cancer Agency, The University of Texas MD Anderson Cancer Center, University of Alberta, University of Calgary, University of Pittsburgh, Allegheny General Hospital, University of Alabama at Birmingham, Magee-Womens Hospital, UPMC Hillman Cancer Center, Centre Hospitalier de l’Université de Montréal, Spring Branch Medical Center, Cross Cancer Institute

OpenAlex ID: A5069660727

S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.

2011 · AHG Paterson, SJ Anderson, et al. · Cancer Research · 18

5-year survival with dose intensive L-FAC multimodality therapy of breast cancer

2004 · K. Jabboury, A. Wong, et al. · Journal of Clinical Oncology · 2

286P Impact of adjuvant endocrine therapy on survival outcomes in female breast cancer patients over 50

2024 · H. Zuo, Y. Yuan, et al. · Annals of Oncology

306P Patient-reported symptoms in early breast cancer and future cardiovascular events: A province-wide administrative database study

2024 · E. Pituskin, K. Joseph, et al. · Annals of Oncology

Adjuvant Breast Radiotherapy Alone (Without Endocrine Therapy) in Women 70 Years or Older with Early-Stage Breast Cancer Post-Breast Conservation Surgery: A Population-Based Long-Term Follow-Up Study

2019 · M. Wang, S. Zebak, et al. · International Journal of Radiation Oncology*Biology*Physics

Abstract P3-12-11: Disparities in adjuvant hormone adherence in breast cancer patients within a universal healthcare model

2018 · ZW Veitch, OF Khan, et al. · Cancer Research

Limited impact of tamoxifen following dose-intensive L-FAC multimodality therapy of breast cancer

2006 · K. W. Jabboury, A. Wong, et al. · Journal of Clinical Oncology

PCN2 AN INTERIM COST AND OUTCOME COMPARISON ALONGSIDE A PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING EARLY INTENSIFICATION WITH BONE MARROW TRANSPLANTATION (BMT) TO CONVENTIONAL DOSE CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH AGGRESSIVE NON-HODGKIN's LYMPHOMA

2002 · AT Adamus, RB Arbuckle, et al. · Value in Health

PCN3 COLLECTION OF INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKIN's LYMPHOMA AND MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING A PALMTM HANDHELD

2002 · KM King, AM Wood, et al. · Value in Health

Works count: 9

Citation count: 20

H-index: 2

I10-index: 1